Melbourne, Australia; Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it will be presenting at the Bio-Europe^® conference held in Cologne, Germany this week. At the conference Starpharma will also be conducting licensing discussions for DEP™ and VivaGel^® with pharmaceutical companies.

Bio-Europe^® is Europe's largest partnering conference for the global biotechnology and life sciences industry, attracting more than 3,600 participants. Attendees at the conference include many of the world’s leading pharmaceutical companies including AbbVie, AstraZeneca, Roche, Sanofi, Pfizer, Amgen, Bayer, Seattle Genetics, and Genentech.

Starpharma’s presentation provides an overview of the DEP^TM drug delivery platform, including DEP^TM docetaxel, DEP™ cabazitaxel and Targeted DEP™ conjugates which have consistently outperformed the original drugs with regard to both efficacy and survival.

Starpharma’s Bio-Europe^® presentation is scheduled for 4:30pm on Tuesday 8 November (CET).

View Presentation:  Bio-Europe Presentation 2016 ( pdf file, 1MB)

Download Announcement: Starpharma to present at Bio-Europe® conference ( pdf file, 94kb)